Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06875609Recruiting

ctDNA in Cutaneous Squamous Cell Carcinoma

Role: collaborator

NCT07025785Not ApplicableRecruiting

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Role: collaborator

NCT06606028Recruiting

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

Role: collaborator

NCT06744296Recruiting

Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

Role: collaborator

All 4 trials loaded